drron
Veteran Member
- Joined
- Jul 4, 2002
- Posts
- 35,659
As if on cue today's MJA has yet another new study on Rheumatoid.Good to hear and hopefully the specialist will be across it. They won't do his knees until a) he lost sufficient weight and b) till after his wife had recovered from her knee replacement and hip replacement which is supposed to happen in 3 months, The weight loss has really helped the pain so I hope he is able to keep it off.
Olumiant (baricitinib) is a breakthrough medication for the treatment of rheumatoid arthritis. The drug is a type of janus kinase (JAK) inhibitor, which blocks the JAK enzymes driving the pro-inflammatory responses seen in rheumatoid arthritis.
JAK inhibitors are different to traditional biologic drugs and offer many benefits. Biologics take the form of large molecules which suppress inflammation from outside of the cells, and they are given by infusion or injection. This can be painful to administer and the therapy does not work for all patients. In contrast, JAK inhibitors are an oral treatment and represent a huge step forward in simplifying therapy for rheumatoid arthritis. Unlike biologics, JAK inhibitors are small molecules which interrupt the enzyme signalling pathway from inside of the cell.
Shown to be slightly more effective than Humira and methotrexate.